Is fludrocortisone indicated for treating tachycardia in an acute Addisonian crisis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fludrocortisone Is Not Indicated for Treating Tachycardia in Acute Addisonian Crisis

Fludrocortisone should not be used to treat tachycardia during an acute Addisonian crisis—immediate IV hydrocortisone 100 mg bolus plus rapid isotonic saline infusion are the only treatments required for the acute phase. 1

Immediate Management of Addisonian Crisis

The tachycardia you observe in Addisonian crisis is a compensatory response to profound hypovolemia and hypotension, not a primary indication for mineralocorticoid therapy. The treatment priorities are:

  • Administer hydrocortisone 100 mg IV bolus immediately without any delay for diagnostic procedures 1, 2
  • Begin rapid IV fluid resuscitation with 0.9% normal saline at 1 L/hour initially, followed by 2-3 additional liters over the next several hours 1, 2
  • Continue IV hydrocortisone at 100 mg every 6-8 hours (or 100-300 mg/day as continuous infusion) for the first 24-48 hours 1, 2
  • Monitor hemodynamics frequently to avoid fluid overload while ensuring adequate resuscitation 1

The tachycardia will resolve as intravascular volume is restored and cortisol deficiency is corrected—it requires no separate pharmacologic intervention.

Why Fludrocortisone Is Withheld During Acute Crisis

Mineralocorticoid replacement with fludrocortisone should only be restarted when the hydrocortisone dose falls below 50 mg/day during the recovery phase. 1 This is because:

  • High-dose hydrocortisone (≥50 mg/day) provides sufficient mineralocorticoid activity by saturating 11β-HSD type 2 receptors, eliminating any need for additional fludrocortisone 3
  • Adding fludrocortisone during the acute phase when patients are receiving stress-dose glucocorticoids offers no benefit and may complicate fluid management 1
  • The glucocorticoid component of hydrocortisone at stress doses already addresses the mineralocorticoid deficiency that contributes to hypotension and electrolyte disturbances 1, 3

Transition to Maintenance Therapy

Once the patient has clinically improved and hydrocortisone is tapered below 50 mg/day (typically after 24-48 hours), you should:

  • Restart fludrocortisone at 0.05-0.1 mg once daily 1, 2
  • Taper stress-dose hydrocortisone over 1-3 days to oral maintenance dosing of 15-25 mg daily in divided doses 1, 2
  • Adjust fludrocortisone dose (typical range 50-200 µg daily) based on blood pressure, orthostatic symptoms, plasma renin activity, and serum electrolytes 1, 4, 5

Common Pitfalls to Avoid

  • Never delay hydrocortisone and IV fluids to administer fludrocortisone first—treatment of suspected adrenal crisis should never be delayed by any diagnostic or therapeutic procedures 1, 6, 2
  • Do not attempt to treat tachycardia with beta-blockers or other rate-control agents—the tachycardia is physiologic compensation for shock and will resolve with volume resuscitation and glucocorticoid replacement 1
  • Avoid premature introduction of fludrocortisone while hydrocortisone remains ≥50 mg/day—this provides no additional benefit and may cause hypokalemia or fluid retention 1, 3
  • Do not undertaper stress-dose glucocorticoids before the precipitating illness has resolved—premature tapering risks recurrent crisis 1, 2

The key principle is that acute Addisonian crisis is a glucocorticoid and volume emergency, not a mineralocorticoid emergency—fludrocortisone plays no role in the acute resuscitation phase. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Adrenal Crisis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Stress‑Dose Glucocorticoid Management and Gout Treatment in Primary Adrenal Insufficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Replacement therapy for Addison's disease: recent developments.

Expert opinion on investigational drugs, 2008

Guideline

Diagnosing Adrenal Insufficiency in Hypo-osmolar Hyponatremia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.